NAVCO Pharmaceuticals Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Geoffrey Lee
Chief executive officer
CA$62.8k
Total compensation
| CEO salary percentage | 71.7% |
| CEO tenure | 11.7yrs |
| CEO ownership | n/a |
| Management average tenure | 1.7yrs |
| Board average tenure | 1.3yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | CA$489k |
| Mar 31 2024 | n/a | n/a | -CA$3m |
| Dec 31 2023 | n/a | n/a | -CA$2m |
| Sep 30 2023 | CA$63k | CA$45k | -CA$2m |
Compensation vs Market: Geoffrey's total compensation ($USD43.68K) is below average for companies of similar size in the German market ($USD469.36K).
Compensation vs Earnings: Insufficient data to compare Geoffrey's compensation with company performance.
CEO
Geoffrey Lee
11.7yrs
Tenure
CA$62,775
Compensation
Mr. Geoffrey Lee is Chief Executive Officer of NAVCO Pharmaceuticals Inc. from April 13, 2013.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 11.7yrs | CA$62.78k | no data | |
| Chief Financial Officer | 1.7yrs | CA$31.60k | 1.55% € 8.9k | |
| COO & Director | 1.7yrs | CA$72.00k | 10.06% € 57.4k | |
| Corporate Secretary & Independent Director | 1.7yrs | CA$55.53k | 3.35% € 19.1k |
1.7yrs
Average Tenure
53yo
Average Age
Experienced Management: F0U's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| COO & Director | 1.7yrs | CA$72.00k | 10.06% € 57.4k | |
| Corporate Secretary & Independent Director | 1.7yrs | CA$55.53k | 3.35% € 19.1k | |
| Independent Director | less than a year | no data | 9.2% € 52.5k | |
| Independent Director | less than a year | no data | 9.2% € 52.5k |
1.3yrs
Average Tenure
42.5yo
Average Age
Experienced Board: F0U's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 07:47 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NAVCO Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|